551 Shares in Boston Scientific Co. (NYSE:BSX) Acquired by Sachetta LLC

Sachetta LLC purchased a new position in Boston Scientific Co. (NYSE:BSX) during the 4th quarter, Holdings Channel reports. The fund purchased 551 shares of the medical equipment provider’s stock, valued at approximately $32,000.

Other institutional investors have also added to or reduced their stakes in the company. Bruce G. Allen Investments LLC bought a new position in Boston Scientific in the fourth quarter worth approximately $28,000. Venturi Wealth Management LLC raised its position in Boston Scientific by 58.0% in the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 215 shares during the period. Motco raised its position in Boston Scientific by 136.3% in the third quarter. Motco now owns 645 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 372 shares during the period. Cetera Trust Company N.A bought a new position in Boston Scientific in the fourth quarter worth approximately $43,000. Finally, Asset Dedication LLC raised its position in shares of Boston Scientific by 42.6% during the 3rd quarter. Asset Dedication LLC now owns 786 shares of the medical equipment provider’s stock valued at $41,000 after purchasing an additional 235 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Trading Down 0.4 %

Shares of BSX opened at $75.37 on Thursday. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $76.25. The company has a 50-day moving average of $70.27 and a 200 day moving average of $63.46. The firm has a market capitalization of $110.58 billion, a price-to-earnings ratio of 63.34, a PEG ratio of 2.60 and a beta of 0.77. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.05. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. The company had revenue of $3.86 billion during the quarter, compared to analyst estimates of $3.68 billion. On average, research analysts expect that Boston Scientific Co. will post 2.32 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Oppenheimer raised their price objective on shares of Boston Scientific from $58.00 to $68.00 and gave the company a “market perform” rating in a research report on Thursday, February 1st. Mizuho raised their price objective on shares of Boston Scientific from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, May 15th. Citigroup raised their price objective on shares of Boston Scientific from $85.00 to $87.00 and gave the company a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. raised their price objective on shares of Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Finally, Robert W. Baird lifted their price target on shares of Boston Scientific from $79.00 to $84.00 and gave the company an “outperform” rating in a report on Thursday, April 25th. Three investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $75.41.

Insider Activity

In other news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $66.35, for a total value of $463,322.05. Following the completion of the sale, the executive vice president now owns 53,788 shares in the company, valued at approximately $3,568,833.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $66.35, for a total transaction of $463,322.05. Following the completion of the transaction, the executive vice president now owns 53,788 shares in the company, valued at approximately $3,568,833.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP John Bradley Sorenson sold 16,351 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $69.30, for a total transaction of $1,133,124.30. Following the transaction, the executive vice president now owns 50,638 shares of the company’s stock, valued at approximately $3,509,213.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 74,599 shares of company stock worth $5,286,149. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.